Back

The impact of electroanatomical mapping and VT substrate ablation on primary and secondary prevention ICD indication in patients with repaired Tetralogy of Fallot

16 April 2023 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Ventricle - Round 2 - Ablation Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2023

About the speaker

Photo
Doctor Yoshitaka Kimura

Leiden University Medical Center, Leiden (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Machine learning based prediction of 1-year arrhythmia recurrence after ventricular tachycardia ablation in patients with structural heart disease
Doctor F. Komlosi (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Clinical significance of conduction velocity orientation vectors on cardiac mapping surfaces
Doctor R. Anderson (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
A novel workflow for advanced mapping of repolarization dispersion from endocardial unipolar electrograms in patients with coved-type brugada syndrome
Miss S. Latrofa (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Impact of cardiac sympathetic denervation on electrical storms in patients with cardiomyopathies
Doctor V. Dusi (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Recurrences of ventricular tachycardia after stereotactic arrhythmia radioablation arise outside the treated volume: analysis of the Swiss cohort
Doctor C. Herrera Siklody (Bern, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricle - Round 2 - Ablation
Video

The Event

Event poster

EHRA 2023

16 April - 18 April 2023
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources